Metformin
Also known as: Glucophage, Fortamet, Glumetza
An AMPK activator commonly used alongside GLP-1 peptides and metabolic peptides to enhance glucose control and longevity outcomes.
Research Status
FDA-approved
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs in 20-30% of users, especially with immediate-release formulations. Usually resolves within 1-2 weeks. Taking with food significantly reduces incidence. Extended-release formulations are better tolerated. Gradual dose titration minimizes GI effects.
Reported in 3-5% of users. Usually mild and self-resolving. More common with higher doses. Does not require discontinuation.
Occurs in 10-30% of long-term users due to reduced B12 absorption in the terminal ileum. Annual B12 monitoring recommended. Supplementation may be needed. Risk increases with duration of use and higher doses.
Incidence <1 per 1000 patient-years in patients with normal renal function. Risk increases significantly with renal impairment (eGFR <30), acute illness, dehydration, or contrast dye procedures. Requires immediate medical attention. Symptoms include muscle pain, difficulty breathing, unusual fatigue.
May occur with long-term use due to reduced folate absorption. Less common than B12 deficiency. Periodic monitoring recommended, especially in women of childbearing age.
Metformin alone does not cause hypoglycemia. Risk increases only when combined with insulin or insulin secretagogues (sulfonylureas). Rare when used as monotherapy.
Risk increases in patients with pre-existing renal disease, acute illness, dehydration, or contrast dye exposure. Renal function should be assessed before initiation and monitored periodically. Contraindicated in severe renal impairment.
Reported in 1-3% of users. Usually mild and self-resolving. May be related to initial metabolic changes.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 500-2000 mg |
| Frequency | 1-3x daily |
| Timing | With meals to reduce gastrointestinal side effects |
| Route | Subcutaneous |
Standard clinical dosing ranges from 500mg daily to 2000mg daily in divided doses. Extended-release formulations allow once-daily dosing. For research purposes, dosing should follow published protocols and institutional guidelines.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 129.16 g/mol |
| Half-life | 4-9 hours (immediate-release); 7-16 hours (extended-release) |
Metformin is an oral biguanide that activates AMP-activated protein kinase (AMPK), a master metabolic regulator. It improves insulin sensitivity by reducing hepatic glucose production and enhancing peripheral glucose uptake. Metformin also modulates gut microbiota and mitochondrial function, contributing to improved metabolic health and potential longevity benefits.
AMPK Activation
Metformin activates AMPK, which phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA and increasing fatty acid oxidation. This enhances mitochondrial function and energy metabolism.
Hepatic Glucose Production
Metformin decreases gluconeogenesis in the liver by reducing hepatic energy state and inhibiting complex I of the mitochondrial electron transport chain, lowering fasting glucose levels.
Peripheral Glucose Uptake
Metformin enhances insulin-stimulated glucose uptake in skeletal muscle and adipose tissue, improving whole-body insulin sensitivity independent of pancreatic insulin secretion.
Gut Microbiota Modulation
Metformin alters the composition and function of gut bacteria, increasing short-chain fatty acid production and improving intestinal barrier function, which contributes to metabolic improvements.
Mitochondrial Function
Metformin improves mitochondrial biogenesis and function through AMPK-dependent and independent mechanisms, enhancing cellular energy production and reducing oxidative stress.
- AMPK activation is the primary mechanism linking metformin to metabolic improvements and potential longevity effects
- Metformin reduces hepatic glucose production more effectively than it enhances peripheral glucose uptake
- The drug does not stimulate insulin secretion, making it safe for use in non-diabetic individuals
- Metformin's effects on gut microbiota may contribute significantly to its metabolic benefits beyond direct AMPK activation
- Long-term metformin use requires monitoring of vitamin B12 levels and renal function
Track your Metformin research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Metformin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.